ERA and SGLT2 Inhibitor Combo Cuts Albuminuria in Chronic Kidney Disease
(MedPage Today) -- PHILADELPHIA -- A low-dose, investigational endothelin A receptor antagonist paired with an SGLT2 inhibitor reduced albuminuria in patients with chronic kidney disease (CKD) in the phase IIb ZENITH-CKD trial.
By week 12 of...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Heart | SGLT2 Inhibitors | Urology & Nephrology